A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors

被引：0
|
作者：
Ji, Dongmei
Weitao, Yao
Tong, Xiangmin
Zhang, Chenping
Wang, Feng
Chen, Zhendong
Zhou, Yuhong
Li, Zhendong
Deng, Yaotiao
Huang, Gang
Tao, Zhiwei
Zheng, Yulong
Wang, Gang
Liu, Guowen
Chen, Jing
Niu, Xiaohui
Yang, Jilong
Pang, Weijia
Zhao, Min
Hu, Xichun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Orthoped, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] ZheJiang Prov Peoples Hosp, Dept Hematol, Hangzhou, Peoples R China
[5] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[7] Anhui Med Univ, Affiliated Hosp 2, Dept Oncol, Hefei, Peoples R China
[8] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China
[9] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[10] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[11] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Orthoped & Soft Tissue, Changsha, Peoples R China
[12] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Univ Sci & Technol China, Affiliated Hosp 1, Hefei, Peoples R China
[15] Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China
[16] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China
[17] Beijing Jishuitan Hosp, Beijing, Peoples R China
[18] Beijing Jishuitan Hosp, Beijing, Peoples R China
[19] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[20] ImmVira Co Ltd, Shenzhen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：1
相关论文
共 50 条
  • [41] INITIAL RESULTS OF A PHASE 1 TRIAL OF RP2, A FIRST IN CLASS, ENHANCED POTENCY, ANTI-CTLA-4 ANTIBODY EXPRESSING, ONCOLYTIC HSV AS SINGLE AGENT AND COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS
    Aroldi, Francesca
    Sacco, Joseph
    Harrington, Kevin
    Olsson-Brown, Anna
    Nanclares, Pablo
    Menezes, Lavita
    Bommareddy, Praveen
    Thomas, Suzanne
    Kaufman, Howard
    Samakoglu, Selda
    Coffin, Robert
    Middleton, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A256 - A257
  • [42] A PHASE 1B/2 STUDY OF A NOVEL ANTI-CTLA-4 NEOBODYTM ADG116 MONOTHERAPY AND IN COMBINATION WITH TORIPALIMAB (TORI; ANTI-PD-1 ANTIBODY) IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS
    Park, John
    Hsien, Matthew
    Richardson, Gary
    Tolcher, Anthony
    Chon, Hong Jae
    Shin, Sang Joon
    Lim, Ho Yeong
    Hamid, Anis
    Li, Daneng
    Shi, Kristine
    Zheng, Songmao
    Liu, Guizhong
    Li, Ai
    Zhu, Lvyu
    Dai, Ruby
    Peng, Wei
    Lowe, Dana
    Luo, Peter
    Zha, Jiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A785 - A785
  • [43] An open-label, multicenter, phase II study of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for salvage therapy in patients with HER2-expressing advanced solid tumors(PRaG3.0).
    Xu, Meiling
    Kong, Yuehong
    Xing, Pengfei
    Chen, Rongzheng
    Ma, Yifu
    Shan, Chanchan
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China.
    Wang, Jie
    Sun, Yuping
    Chu, Qian
    Duan, Jianchun
    Wan, Rui
    Wang, Zhijie
    Zhao, Jun
    Li, Haoyuan
    Guo, Yingmei
    Chen, Yuling
    Wang, Yan
    CANCER RESEARCH, 2022, 82 (12)
  • [45] Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcgRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1
    Carneiro, Ana
    Yachnin, Jeffrey
    Aljumaily, Raid
    Abel, Edvard
    Falchook, Gerald Steven
    Ji, Yan
    Borggren, Marie
    Martensson, Linda
    Gertsson, Susanne
    Karlsson, Ingrid
    Teige, Ingrid
    Tehranchi, Ramin
    Wallin, Johan Erik
    Chisamore, Michael Jon
    Frendeus, Bjorn
    McAllister, Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] FIRST-IN-HUMAN PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: INITIAL PHASE 1 RESULTS
    Friedman, Claire
    Ascierto, Paolo
    Davar, Diwakar
    O'Hara, Mark
    Shapira-Frommer, Ronnie
    Dallos, Matthew
    Khemka, Vivek
    James, Lee
    Fischer, Bruce
    Demes, Shilpa
    Li, Li
    Kozicki, Martin
    Ravindran, Palanikumar
    Xu, Ke
    Kollia, Georgia
    Shoukry, Jacqueline
    Yunan, Mona
    Massey, Ashish
    Gutierrez, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A239 - A239
  • [47] Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors.
    Hickingbottom, Barbara
    Clynes, Raphael
    Desjarlais, John
    Li, Caiyan
    Ding, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
    Jung, Kyung Hae
    LoRusso, Patricia
    Burris, Howard
    Gordon, Michael
    Bang, Yung-Jue
    Hellmann, Matthew D.
    Cervantes, Andres
    Ochoa de Olza, Maria
    Marabelle, Aurelien
    Hodi, Stephen
    Ahn, Myung-Ju
    Emens, Leisha A.
    Barlesi, Fabrice
    Hamid, Omid
    Calvo, Emiliano
    McDermott, David
    Soliman, Hatem
    Rhee, Ina
    Lin, Ray
    Pourmohamad, Tony
    Suchomel, Julia
    Tsuhako, Amy
    Morrissey, Kari
    Mahrus, Sami
    Morley, Roland
    Pirzkall, Andrea
    Davis, S. Lindsey
    CLINICAL CANCER RESEARCH, 2019, 25 (11) : 3220 - 3228
  • [49] First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with other solid tumors: Safety and efficacy results from a phase I study.
    Bai, Xueli
    Xu, Qin
    Liang, Xinjun
    Chu, Qian
    Zhang, Xiaochen
    Chen, Yiwen
    Xu, Nong
    Fang, Weijia
    Shan, Jianzhen
    Jiang, Weiqin
    Zhou, Jianya
    Zheng, Yu-Long
    Long, Sixiang
    Chen, Haonan
    Zhao, Li
    Wang, Hongli
    Sun, Jiya
    Sun, Xing
    Zhou, Hui
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors
    Xu, Meiling
    Chen, Rongzheng
    Xing, Pengfei
    Kong, Yuehong
    Zhao, Xiangrong
    Zhang, Junjun
    Cai, Shang
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345